Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis

American Journal of Clinical Dermatology

Volumn 10, Issue 4, 2009, Pages 229-237

  Ingram, John R ^a   Martin, Julie A ^a   Finlay, Andrew Y ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; HYDROCORTISONE ACETATE; METHYLPREDNISOLONE ACEPONATE; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BURNING SENSATION; CAREGIVER; CLINICAL TRIAL; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM;

ADMINISTRATION, CUTANEOUS; ADULT; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; QUALITY OF LIFE; TACROLIMUS; TREATMENT OUTCOME;

EID: 67650467296     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/00128071-200910040-00003     Document Type: Review

References (77)

1. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205-13
2. Williams HC, Wuethrich B. The natural history of atopic dermatitis. In: Williams HC, editor. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press, 2000: 41-59
3. The International Study of Asthma and Allergies in Childhood (ISAAC). Worldwide variation in prevalence of symptoms of asthma, allergic rhino-conjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 225-32
4. Diepgen TL, Blettner M. Analysis of familial aggregation of atopic eczema and other atopic diseases by ODDS RATIO regression models. J Invest Dermatol 1996; 106: 977-81
5. Larsen FS, Holm NV, Henningen K. Atopic dermatitis: a genetic-epidemiologic study in apopulation-based twin sample. J Am Acad Dermatol 1986; 15: 487-94
6. Williams HC, Pembroke AC, Forsdyke H, et al. London-born black Caribbean children are at increased risk of atopic dermatitis. J Am Acad Dermatol 1995; 32: 2120-7
7. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life (QOL) in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006; 155: 145-55
8. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in pre-school children? Br J Dermatol 2001; 143: 514-22
9. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46: 361-70
10. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001; 45 Suppl. 1: S67-8
11. Lewis-Jones MS, Finlay AY. The children's dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-9
12. Lawson V, Lewis-Jones MS, Finlay AY, et al. The family impact of childhood atopic dermatitis: the Dermatitis Family Impactquestionnaire.Br J Dermatol 1998; 138: 107-13
13. Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol (Stockh) 2000; 80: 430-4
14. Finlay AY. Quality of life impairment in atopic dermatitis and psoriasis. Clin Exp Perspect Sandimmun Ther 1992; 2: 10-11
15. Basra MK, Finlay AY. The family impact of skin diseases: the Greater Patient concept. Br J Dermatol 2007; 156: 929-37
16. Whally D, McKenna SP. The impact of childhood atopic dermatitis on the quality of life of the family. PCI J Progress Clin Insights 1999; 7: 10-11
17. Elliot B. Itching agony. Nurs Times 1990; 86: 72
18. Daud LR, Garralda ME, David TJ. Psychosocial adjustment in preschool children with atopic eczema. Arch Dis Child 1993; 69: 670-6
19. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg 1998; 17: 291-6
20. Elliot BE, Luker K. The experiences of mothers caring for a child with severe atopic eczema. J Clin Nurs 1997; 6: 241-7
21. Calman KC. Quality of life in cancer patients: a hypothesis. J Med Ethics 1984; 10: 124-7
22. Holme SA, Man I, Sharpe JL, et al. The Children's Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol 2003; 148: 285-90
23. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomised controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003; 120: 932-41
24. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis; the SCORAD index. Dermatology 1993; 186: 23-31
25. Ben-Gashir MA, Seed PT, Hay RJ. Quality of life and disease severity are correlated in children with atopic dermatitis. Br J Dermatol 2004; 150: 284-90
26. Ben-Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol 2002; 16: 455-62
27. Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Clin Exp Der-matol 2001; 10: 11-8
28. Touw CR, Kakkaari-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis using intermittent ciclosporin. Br J Dermatol 2001; 144: 967-72
29. Wahl A, Burckhardt C, Wiklund I, et al. The Norwegian version of the Quality of Life Scale (QOLS-N): avalidation and reliability study in patients suffering from psoriasis. Scand J Caring Sci 1998; 12: 215-22
30. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931-6
31. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propio-nate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double-blind, parallel group study. BMJ 2003; 326: 1367-72
32. Liu J, Albers MW, Wandless TJ, et al. Inhibition of T-cell signalling by immunophilin-ligand complexes correlates with loss of calcineurin phospha-tase activity. Biochemistry 1992; 31: 3896-901
33. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-73
34. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immuno-suppressant isolated from a Streptomyces: I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-55
35. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28-38
36. Soter NA, Fleischer Jr AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39-46
37. Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S44-57
38. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637- 44
39. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539-46
40. Reitamo S, Harper J, Bos JD, et al. 0.03% tacrolimus ointment applied once or twice daily ismore efficaciousthan 1%hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554-62
41. Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282-9
42. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacro-limus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64
43. Hanifin JM, Leung DYM, Paller A, et al. Tacrolimus ointment monotherapy is safe and effective for the long-term treatment (more than 3 years) of atopic dermatitis in pediatric patients [abstract]. J Allergy Clin Immunol 2003; 111: S130
44. Arai T, Koyama Y, Suenaga T, et al. Ascomycin, an anti-fungal antibiotic. J Antibiot Series A 1962; 15: 231-2
45. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981). Semin Cutan Med Surg 2001; 20: 233-41
46. Meingasser JG, Grassberger M, Fahrngruber H, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 569-76
47. Hultsch T, Muller KD, Meingasser JG, et al. Ascomycin macrolactam deri vative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependant manner. Arch Dermatol Res 1998; 290: 501-7
48. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild to moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504
49. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of non-steroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-62
50. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2-9
51. Meurer M, Föster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-7
52. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic der matitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-84
53. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin deri vative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomised, double-blind, controlled study. BrJ Dermatol 2001; 144: 507-13
54. Kyllonen H, Remitz A, Mandelin JM, et al. Effects of 1 year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-81
55. Naylor M, Elmets C, Jarracz E, et al. Non-melanoma skin cancer in patients with atopic dermatitis treated with topicaltacrolimus.J Dermatol Treat 2005; 16: 149-53
56. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861-73
57. Ashcroft DM, Chen L-C, Garside R, et al. Topical pimecrolimus for eczema. Cochrane Database Syst Rev 2007; (4): CD005500
58. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6
59. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-97
60. Kawashima M, QOL Research Forum for Patients with Atopic Dermatitis. Quality of life in patients with atopic dermatitis: impact of tacrolimus ointment. Int J Dermatol 2006; 45: 731-6
61. Won CH, Seo PG, Park YM, et al. A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatol Treat 2004; 15: 30-4
62. Singalavanija S, Noppakun N, Limpongsanuruk W, et al. Efficacy and safety of tacrolimus ointment in pediatric patients with moderate to severe atopic dermatitis. J Med Assoc Thai 2006; 89: 1915-22
63. Sunderkotter C, Weiss JM, Bextermoller R, et al. Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges 2006; 4: 301-6
64. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-64
65. Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004; 150: 274-83
66. McKenna SP, Whalley D, Dewar AL, et al. International development of the Parents' Index of Quality of LifeinAtopic Dermatitis (PIQoL-AD). Qual Life Res 2005; 14: 231-41
67. Staab D, Kaufmann R, Brautigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial: CASM981CDE04-Study Group. Pediatr Allergy Immunol 2005; 16: 527-33
68. McKenna SP, Doward LC, Meads DM, et al. Quality of life in infants and children with atopic dermatitis: addressing issues of differential item func tioning across countries in multinational clinical trials. Health Qual Life Outcomes 2007; 5: 45
69. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307-19
70. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65-72
71. Whalley D, Huels J, McKenna SP, et al. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002; 110: 1133-6
72. Leo HL, Bender BG, Leung SB, et al. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 691-3
73. Bieber T, Vick K, Folster-Holst R, et al. Efficacy and safety of methyl-prednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007; 62: 184-9
74. McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol 2006; 20: 248-54
75. Meads DM, McKenna SP, Kahler K. The quality of life of parents of children with atopic dermatitis: interpretation of PIQoL-AD scores. Qual Life Res 2005; 14: 2235-45
76. Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-72
77. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ 2005; 330: 516